Peptech vom Handel ausgesetzt - 500 Beiträge pro Seite

[gony]

Peptech ist in Australien zum wiederholten male zum Handel ausgesetzt.PEPTECH LIMITED 2001-04-04 ASX-SIGNAL-G
HOMEX - Sydney
+++++++++++++++++++++++++
ASX MARKET RELEASE
The securities of Peptech Limited will be placed in pre-open pending
the release of an announcement by the Company. Unless ASX decides
otherwise, the securities will remain in pre-open until the earlier
of the commencement of normal trading on 6 April 2001 or when the
announcement is released to the market.
Security Code: PTD
D Barnett
SENIOR COMPANIES ADVISOR
ASX
TRADING HALT REQUEST
Further to your telephone conversation with our Director, Mr Glenn
Morris, Peptech requests the ASX to grant a trading halt on its
shares effective immediately extending to the time when an
announcement can be sent to the ASX and within 48 hours at the
latest.
Peptech is not aware of any reason why the trading halt should not be
granted.
D Mills (BSc, FCA, FCIS)

[bernimaus]

Na, und? Was halten wir davon? Sonst haben sie immer erst die Meldung gebracht, und dann den Handel ausgesetzt...

Schaun wir mal...

[gony]

Ist schon suspekt das man keine Infos im Netz finden kann.
Aber Peptech kann doch nur postiv überraschen.

[gony]

Wie kann es sein das Peptech in Australien ausgesetzt ist un din Frankfurt gehandelt wird??????????????????

[bernimaus]

Peptech hat schließlich die ASX um Handelsaussetzung gebeten, und nicht alle Börsen diese Welt.
Bei den letzten malen sind die anderen Börsen dann irgendwann gefolgt. Müssen sie aber nicht.

Aber es ist doch interessant, zu welchem Kurs heute morgen in Frankfurt gehandelt wurde! ... Oder?

[gony]

Alle Börsen dieser Welt ist ,(glaub ich), ein wenig übertrieben.
Pepi wird ja auch nicht an so vielen gehandelt.
(4) Aus, B, F, Xetra.
Ich kenn es nur so das wenn eine Börse aussetzt, dann setzt der Rest auch aus

[TS80]

Ich würd sagen Peptech ist auch in Deutschland vom
Handel ausgesetzt oder der Makler von PTD ist verschollen
ich krieg jedenfalls zu keinem Kurs Peptechaktien
in Australien hat es heute Morgen einen Geldkurs von
3,600 AUD gegeben mal schauen. Ich frag mich nur
warum dann heute Morgen Order in Deutschland durchgegangen
sind! Ich bin mal gespannt auf Morgen. Um wieviel
Uhr beginnt eigentlich der Handel in Australien

[gony]

Ja stimmt schon, heute morgen ist wohl eine Order in Frankfurt über die Bühne gegangen und dann war Ruhe.
Ach ich mach mir keine Sorgen , wird schon irgendeine Kooperationsvereinbarung sein oder peptech wird von Biogen mit einem Umtauschverhältniss von 1 zu 1 (Spaß)übernommen.
So viel ich weiß fängt die Börse in Australien um 24.00 Uhr MEZ an.
Mal schauen wer morgen als erstes die neusten Ifos ins Netz stellt.
Ich tippe auf Berni.

Schönen Abend noch

[TrapperJohn]

Ich habe heute morgen mal den Kurs in Australien gecheckt und hatte mich gewundert.Ich dachte,daß die Kursfeststellung nur ein Fehler sein kann.
X.PTD Market data delayed minimum 15 minutes


2.940
4/4/01 12:44:27 PM
+2.940
Open Low High Bid / Ask Volume 52wk Range
0.00 0.00 0.00 (1) 3.60 / 3.00 (1) 0 0.235 / 0.85

Gruß
Trapper

Vielleicht auch nicht?

[bernimaus]

@TrapperJohn:
Das sind die Angaben von Stockhouse oder? Die sind nicht immer aktuell...

@gony: Habe leider zur Zeit keinen guten Draht an die ASX. Krich immer nur Fehlermeldungen, wenn ich Kurse oder Informationen abrufen will. Habe die ASX schon angemailt. Mal sehen, ob sie sich melden.

Also dann wird es doch nochmal richtig spannend, was? Falls das stimmt mit dem Kurs von 3,6schießmichtot Aus$ heute früh, dann geht ja bald richtig die "Sau" los...

Jedenfalls war es bei den letzten Bekanntmachungen von Peptech ja auch so. Wenn da die Händler nicht den Finger drauf getan hätten, wären die Stücke schon vor Wochen für um die 4Aus$ über den Tisch gegangen...

Gruß, Bernimaus

[TrapperJohn]

PTD Peptech Limited
Last Trade: 4/4 22:44 EDT
Last Change % Change Hi Low Open Vol
2.9400 -.1600 -5.16 3.0000 2.9000 3.0000 467,134

Detailed Quote | Company News
Total Return Analysis





All prices are 20 minutes delayed.

**************************************************

Hallo Bernimaus!
Die Kurse hatte ich von Stockhouse.Nachdem ich Dein Posting gelesen habe,habe ich jetzt noch bei Bloomberg Australien nachgeschaut und dieses gefunden.Ich schätze mal,daß der Kurs durch die Decke gegangen wäre,hätte die ASX Peptech nicht aus dem Handel genommen.Was anderes kann ich mir eigentlich nicht vorstellen,da der letzte Handel am 04.04. stattgefunden hat.Heute gab es also keinen Handel mit Peptech.

Gruß
Trapper

[gony]

Servus Peptech ist wieder da.
Handel in Australien bei 3,12 Aus $, sie haben eine englische Biotechfirma mit 33,6 % übernommen.PEPTECH LIMITED 2001-04-06 ASX-SIGNAL-G
HOMEX - Sydney
+++++++++++++++++++++++++
Peptech wishes to announce that it has entered into a subscription
agreement to subscribe up to 33.6% in the capital of Diversys Ltd
("Diversys"). Peptech has also entered into a Joint Research
Collaboration with Diversys.
Diversys, a start up company based in Cambridge, UK, is developing a
range of platform technologies for the in vitro evolution and
engineering of recombinant proteins, including antibodies. The field
of protein engineering, including antibodies, is showing immense
potential and is expected to yield both new medicines together with
vital diagnostic and proteomic tools. Antibody based therapeutics are
projected to command a US$10 billion dollar worldwide market by 2005.
Peptech aims to be a major player in this field and that of protein
and peptide therapeutics. As part of this strategy Peptech has forged
an alliance with Diversys.
Diversys has a number of very important intellectual properties based
on antibodies and on engineered proteins, including several exclusive
or co-exclusive licences to granted patents and patent applications
assigned from the UK Medical Research Council. Diversys has exclusive
rights for a method of making antibody single domains. These are
proteins less than 10% of the size of natural antibodies with binding
activities. It is thought that single domains may have advantages
over natural antibodies of greater tissue permeability and ability to
block the active sites of enzymes and receptors; single domains may
be particularly useful for blocking of virus and bacterial infections
as well as in the treatment of some human diseases. Diversys believes
that single domain antibodies will also have broad applicability in
proteomic and diagnostic applications and therefore it is expected
that Diversys will apply their Intellectual Property Portfolio in the
development of therapeutic single domain antibody, proteomics and
diagnostics fields in conjunction with partners. Under the Joint
Research Collaboration Agreement, Diversys will devise and implement
a research and development programme on behalf of Peptech against
four targets chosen by Peptech.
Diversys was founded in 2000 by Dr Greg Winter and Dr Ian Tomlinson,
the UK Medical Research Council (MRC) and MVM Limited, a UK based
venture Company.
Dr Winter CBE, FRS, PhD and Dr Tomlinson PhD are two world-leading
scientists from the Medical Research Council`s Laboratory for
Molecular Biology (MRC-LMB) Cambridge, England. Drs Winter and
Tomlinson are experts in making recombinant human antibodies by phage
display; indeed Dr Winter was responsible for the invention and
development of the most widely used commercialized technologies for
development of humanized and synthetic antibodies which are currently
on trial like Knoll AG`s D2E7, or which like the world`s largest
selling antibody, Abbott`s Synagis, an anti-viral for RSV and
Genetec`s Herceptin have entered the market a few years ago. Further
he was a Founder and Director of Cambridge Antibody Technology a
company listed on the UK stock exchange with a market capitalisation
of approximately A$2 billion.
The MRC-LMB with ten Nobel prize winners to its credit has strong
links to Cambridge University. One particular strength of the MRC-LMB
is in making antibodies; scientists at the MRC-LMB have pioneered
most current methods for making antibodies, including the creation of
mouse monoclonal antibodies by cell fusion (hybridomas) and human or
humanised antibodies by recombinant DNA technology. The MRC as a
result of its licencing of intellectual property, has become a
significant shareholder in Diversys. Diversys under a three year
research collaboration agreement is allowed to second several
employees to the MRC-LMB, and the MRC has agreed to assign or license
Diversys all intellectual property generated by the research teams
during this period.
MVM Limited finances and builds companies that develop world-class
technology with a clear focus on products for major life science
markets. MVM manages the UK Medical Ventures Fund No 1 - a fund
whose capital is provided by sophisticated institutional investors.
MVM`s investment team has extensive experience in starting, financing
and growing healthcare companies and have been responsible for
creating, managing and funding a large number of successful
technology companies both in Europe and in the United States.
Under the subscription agreement, Peptech will subscribe for shares
in Diversys in three tranches. The first tranche is for the
subscription of 4,075,000 shares for US$3.5 million, the second for
2,037,500 for US$1.75 million one year from the initial subscription
and the third for 2,037,500 for US$1.75 million one year after the
second subscription. Upon the completion of the three subscriptions,
Peptech will hold 33.6% in the capital of Diversys, making us the
largest shareholder.
Under the Joint Research Collaboration Agreement, Peptech undertakes
to pay Diversys a total of US$10 million over a three-year period.
Under this Agreement, Diversys will devise and implement a research
and development programme in respect of four targets that Peptech
will choose.
Dr Winter has agreed and will be appointed to Peptech`s board as a
non-executive director at the next board meeting. We are extremely
pleased that Dr Winter has agreed to accept the invitation for the
appointment to the Board of Peptech. His appointment will immensely
strengthen the scientific capabilities of our Board. The association
with Diversys will be maintained through Dr Winter and the
appointment of the Managing Director of Peptech to the Board of
Diversys.
Funds for the subscription and joint research collaboration will be
from Peptech`s internally generated funds. It is envisaged that
Peptech will not have to resort to borrowing to fund the above
outlined investments. The cashflow that can be generated from the
recently concluded license agreements with Centocor and Knoll AG will
ensure continued cash inflow. The possible successful outcomes with
Celltech and Immunex would augment that cash inflow.
The Board of Peptech will soon be further strengthened by the
appointment of a prominent Australian immunologist as our Chief
Scientific Officer. The appointment of Dr Winter to the Board, the
contributions expected from the recently formed Scientific Advisory
Board and the appointment of the Chief Scientific Officer, will
ensure that we have the team to enable Peptech to become a key player
in the field of protein and peptide therapeutics.
Selection of the four targets under the Joint Research Collaboration
Agreement has commenced. The development outlined above has firmly
pointed the future direction that your Board has charted for Peptech.
I am sure that you would agree that it is an immensely exciting one.
The choice of the alliance with Diversys was made in full recognition
of the high credentials of Drs Winter and Tomlinson and the alliance
will place Peptech firmly in the International scene.
A corporate presentation to the investment community will be made by
Dr Winter and Mr Bob Connelly (CEO) for Diversys and Stephen Kwik for
Peptech in Sydney on April 10, 2001. The presentation will be made
available on the Peptech website at www.peptech.com.
S Kwik

[bernimaus]

Sauber, sauber, gony. Das klingt doch gut! Die Jungs aus Australien versuchen ja ziemlich konsequent in Europa ein Fuß in die Tür zu bekommen.

Übrigens komme ich immer noch nicht auf die Seiten der ASX. Obwohl mir die nette Dame in Windeseile auf mein Mail geantwortet hat! Respekt. (ich hatte die ASX angemailt, weil ich immer nur Fehlermeldungen bekam...)

Vielen Dank also, dass Du mich nicht im Dunkeln läßt.
Bernimaus

[gony]

Noch ein Bericht:
Berni ich will ja nicht indiskret sein, aber hast du noch Peplin nachgeledt und es würde mich interess. wieviele Pepis du hast.Peptech announces UK acquisition
April 6, 2001
Sydney based biotechnology, Peptech (PTD) announced today that that it will acquire just under 37% of UK based company, Diversys for US$7 million. It will also announced a US$10 million research collaboration with the same company.

Diversys, a start up company based in Cambridge, UK, is developing a range of platform technologies for the in vitro evolution and engineering of recombinant proteins, including antibodies.

Under the subscription agreement, Peptech will subscribe for shares in Diversys in three tranches. The first tranche is for the subscription of 4,075,000 shares for US$3.5 million, the second for 2,037,500 for US$1.75 million one year from the initial subscription and the third for 2,037,500 for US$1.75 million one year after the second subscription.

Upon the completion of the three subscriptions, Peptech will hold 33.6% in the capital of Diversys, making it the largest shareholder.

Under the Joint Research Collaboration Agreement, Peptech undertakes to pay Diversys a total of US$10 million over a three-year period. Under this Agreement, Diversys will devise and implement a research and development programme in respect of four targets that Peptech will choose.

Diversys has a number of intellectual properties based on antibodies and on engineered proteins, including several exclusive or co-exclusive licences to granted patents and patent applications assigned from the UK Medical Research Council.

Diversys has exclusive rights for a method of making antibody single domains. These are proteins less than 10% of the size of natural antibodies with binding activities.

According to the announcement, Peptech aims to be a major player in this field and that of protein and peptide therapeutics. As part of this strategy Peptech has forged an alliance with Diversys.

Diversys believes that single domain antibodies will also have broad applicability in proteomic and diagnostic applications and therefore it is expected that Diversys will apply their Intellectual Property Portfolio in the development of therapeutic single domain antibody, proteomics and diagnostics fields in conjunction with partners.

Under the Joint Research Collaboration Agreement, Diversys will devise and implement a research and development programme on behalf of Peptech against four targets chosen by Peptech.

Diversys was founded in 2000 by Dr Greg Winter and Dr Ian Tomlinson, the UK Medical Research Council (MRC) and MVM Limited, a UK based venture Company.

Dr Winter has agreed and will be appointed to Peptech`s board as a non-executive director at the next board meeting. The association with Diversys will be maintained through Dr Winter and the appointment of the Managing Director of Peptech to the Board of Diversys.

Funds for the subscription and joint research collaboration will be from Peptech`s internally generated funds. It is envisaged that Peptech will not have to resort to borrowing to fund the above outlined investments. The cashflow that can be generated from the recently concluded license agreements with Centocor and Knoll AG will ensure continued cash inflow.

The company also intimated some more success with Celltech and Immunex would augment that cash inflow.

SHAW Stockbroking`s technology analyst, Mr David Cooper said: "Peptech`s entry into this joint venture should increase its international exposure and further diversify its intelectual property assests"

At 1041 AEST Peptech shares were 24c, or over 8% higher at $3.18.

[bernimaus]

hallo gony,

indiskret biste nicht, aber ganz schön neugierig...
Aber natürlich krichste auch auf sooone Fragen eine Antwort:
Ich nenne ein paar tausend Peptech und ein paar hundert Peplins. Zweitere gibst ja leider nur an ganz besonderen Tagen einzeln zugeteilt...

Hast Du am Schluß des Artikels gelesen, dass die Sache mit Immunex und Celltech nun anläuft? Das gibt den nächsten Schub!

Bernimaus

[gony]

Der Jurs geht runter.
Hier die neuste Veröffentlichung der AFX, was es heißt:
Keine Ahnung!!!???


Appendix 3B - Exercise of Options
4/10/01


PEPTECH LIMITED 2001-04-10 ASX-SIGNAL-G
HOMEX - Sydney
+++++++++++++++++++++++++
APPENDIX 3B
NEW ISSUE ANNOUNCEMENT
APPLICATION FOR QUOTATION OF ADDITIONAL SECURITIES AND AGREEMENT
Information or documents not available now must be given to ASX as
soon as available. Information and documents given to ASX become
ASX`s property and may be made public.
Introduced 1/7/96. Origin Appendix 5. Amended 1/7/98, 1/9/99,
1/7/2000.
Name of Entity
Peptech Limited
ACN or ARBN
002 951 877
We (the entity) give ASX the following information.
PART 1 - ALL ISSUES
You must complete the relevant sections (attach sheets if
there is not enough space).
1. Class of securities issued Ordinary shares
or to be issued


2. Number of securities issued 300,000
or to be issued (if known)
or maximum number which
may be issued
3. Principal terms of the securities -
(eg, if options, exercise price
and expiry date; if partly paid
securities, the amount
outstanding and due dates for
payment; if convertible securities,
the conversion price and dates
for conversion)
4. Do the securities rank equally Yes
in all respects from the date
of allotment with an existing
class of quoted securities
If the additional securities
do not rank equally, please
state:
* the date from which they do
* the extent to which they
participate for the next
dividend, (in the case of
a trust, distribution) or
interest payment
* the extent to which they do
not rank equally, other than
in relation to the next
dividend, distribution or
interest payment
5. Issue price or consideration 300,000 at 30c
6. Purpose of the issue (if Exercise of options
issued as consideration for
the acquisition of assets,
clearly identify those
assets)
7. Dates of entering securities 10/04/2001
into uncertified holdings
or despatch of certificates



NUMBER CLASS
8. Number and class of all 145,681,595 Ordinary Fully Paid
securities quoted on
ASX (including the
securities in clause
2 if applicable)
NUMBER CLASS
9. Number and class of all 8,324,628 Share Options
securities not quoted (List attached)
on ASX (including the
securities in clause 2
if applicable)
10.Dividend policy (in the case -
of a trust, distribution
policy) on the increased
capital (interests)
PART 2 - BONUS ISSUE OR PRO RATA ISSUE
Items 11 to 33 are Not Applicable
PART 3 - QUOTATION OF SECURITIES
You need only complete this section if you are applying for quotation
of securities



34. Type of securities (tick one)
(a) X Securities described in Part 1
(b) All other securities
Example: restricted securities at the end of the escrowed period,
partly paid securities that become fully paid, employee incentive
share securities when restriction ends, securities issued on expiry
or conversion of convertible securities
Entities that have Ticked Box 34(a)
Additional Securities Forming a New Class of Securities
(If the additional securities do not form a new class, go to 43)
Tick to indicate you are providing the information or documents
35. The names of the 20 largest holders of the additional
securities, and the number and percentage of
additional securities held by those holders
36. A distribution schedule of the additional securities
setting out the number of holders in the categories
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 - and over
37. A copy of any trust deed for the additional securities
(now go to 43)
Entities that have Ticked Box 34 (b)
Items 38 to 42 are Not Applicable
ALL ENTITIES
Fees
43. Payment method (tick one)
Cheque attached
Electronic payment made
Note: Payment may be made electronically if Appendix 3B is
given to ASX electronically at the same time.



X Periodic payment as agreed with the home branch has been
arranged
Note: Arrangements can be made for employee incentive
schemes that involve frequent issues of securities.
QUOTATION AGREEMENT
1. Quotation of our additional securities is in ASX`s absolute
discretion. ASX may quote the securities on any conditions it
decides.
2. We warrant to ASX that the issue of the securities to be quoted
complies with the law and is not for an illegal purpose, and that
there is no reason why those securities should not be granted
quotation. We warrant to ASX that an offer of the securities for
sale within 12 months after their issue will not require
disclosure under section 707(3) of the Corporations Law.
3. We will indemnify ASX to the fullest extent permitted by law in
respect of any claim, action or expense arising from or connected
with any breach of the warranties in this agreement.
4. We give ASX the information and documents required by this form.
If any information or document not available now, will give it to
ASX before quotation of the securities begins. We acknowledge that
ASX is relying on the information and documents. We warrant that
they are (will be) true and complete.
D M Mills
COMPANY SECRETARY
10/04/2001
PEPTECH LIMITED SECURITIES
ORDINARY SHARES REF NUMBER
Fully paid ords PTD 145,681,595
OPTIONS
EXPIRY DATE EXERCISE REF NUMBER
PRICE
05 Sept 01 Various PTDAM/A 180,000
11 Nov 01 $0.61 PTDAW 200,000
25 Jun 02 $0.62 PTDAO 1,612,903
25 Jun 02 $1.00 PTDAQ 403,225
21 Dec 03 $0.65 PTDAZ 108,500
07 Jun 04 $0.53 PTDAB 1,075,000
07 Jun 07 $0.53 PTDAC 875,000
08 Mar 04 $0.42 PTDAE 90,000
01 Jan 03 $0.42 PTDAD 75,000
02 Oct 05 $0.30 PTDAG 2,610,000
20 Nov 05 $1.21 PTDAF 1,095,000

[toepperkatze]

Gony
Den Text hatte ich bereits am 2.4 ins Bord gesetzt,auf Deine Frage hin sogar mit Übersetzung.
Es geht um Kapitalerhöhungen.
Charttechnisch sieht der Kurs im Moment nicht so gut aus.
Es werden neue Signale benötigt um den Kurs nachhaltig zu steigern. Der Kursanstieg bis dato war die Einpreisung der Aufnahme in den S&P 200.
TK

[gony]

Sorry, du hast recht.
Hab den Text nur reingestellt, weil er das Datum 10.04.01 trug.
Meint ihr da gibt es für die Aktionäre irgendwelche Vorzugsrechte?

36. Ein Verteilung-Plan der zusätzlichen Wertpapiere
sich Lage der Zahl von Haltern in den Kategorien
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 - und übe

Außerdem zeigt leider die Erfahrung, das sich eine Kapitalerhöhung immer negativ auf den Kurs auswirkt.

[TS80]

Für mich sieht es eher nach Daten der Vergangenheit
aus die noch unklar sind und nachgeprüft werden müßen.
Glaube auch, dass der Kurs einen neuen Anlauf nehmen
muß um neue Höchstkurse zu erreichen. Dieser Ausbruch
kann jedoch jederzeit beginnen. Bin noch nicht so lange bei
Peptech dabei, wie war das mit Celltech? Wann kann man
mit Geschäftszahlen rechnen?

[gony]

Neuste Nachricht:

PEPTECH LIMITED 2001-04-12 ASX-SIGNAL-G
HOMEX - Sydney
+++++++++++++++++++++++++
NOTICE OF DIRECTOR`S INTERESTS
Section 205G of the Corporations Law
UPDATING NOTICE
Name of Director Stephen Kwik
Name of Company Peptech Limited
Date of Last
Notification to ASX 14/02/2001
Date Director`s
Interest Changed 10/04/2001


I have a relevant interest in the following securities of the
company or related bodies corporate:
640,000 ordinary shares



A further 300,000 shares acquired on exercise of share options
on 10/04/2001
I have an interest in the following contracts to which I am entitled
to a benefit that confers a right to call for or deliver shares in,
debentures of, interests in a collective investment scheme made
available by, the company or a body corporate:
-

[gony]

Also ich verstehe es so:
Der Kerl hat wohl schon 600.000 Aktien und zeigt an das er weitere 300.000 Stück sich zulegen will.
Eigentlich ne positive Aussage, oder?
Kennt einer ein gutes Übersetzungprogramm aus dem Internet.
Dieser Text wurde von Lycos übersetzt, aber ihr"lest" ja selbst:

Ich habe ein relevantes Interesse an der folgenden Sicherheit der Firma oder in Verbindung stehender korporativer Körper: 640,000 Stammaktien ein weiter 300,000 Anteile erworben auf Übung von Aktienoptionen am 10/04/2001, zu dem ich ein Interesse an den folgenden Verträgen habe, die ich zu einem Nutzen der berechtigt werde, teilen ein Recht zu, zu verlangen oder Anteile in, Schuldscheine dessen zu liefern, Interessen an einem gesammelten Investitionsschema machten vorhanden durch, die Firma oder ein korporativer Körper

[Age32]

Hey was ist los. Sind alle im Urlaub ?
Was passiert mit unseren schönen Pepis ?
Ist die Aktie jetzt schon im S&P200 gelistet ?
Prognosen für Mai ?

[gony]

Nö, ich bin auch noch da.
Momentan ist es eher ruhig und Pepi hatt die letzte Woche von wg. allg. Kurssteigerungen verschlafen, da andere Werte wieder in den Vordergrund gerückt sind.
Momentan stabil bei 1,50, aber mann muß wachsamm sein , denn die hohe Kurssteigerung kann auch ganz schnell sich wieder in die andere Richtung drehen.
Im ganzen sehe ich aber positiv in Hinblick auf neue Nachrichten.
Also Augen auf.